WinSanTor

Executive Summary

WinSanTor is a clinical-stage biotechnology company dedicated to developing novel small molecule therapies for peripheral neuropathies, including diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy (CIPN), and HIV-associated neuropathy. The company's lead program targets DPN, a condition affecting over 20 million patients in the US alone, with an urgent need for disease-modifying treatments beyond symptomatic management. WinSanTor's platform leverages proprietary insights into neuronal metabolism and cellular stress pathways to design therapies that may reverse nerve damage rather than just alleviate pain. The company is currently advancing a Phase 3 trial for its lead candidate, WST-001, and has generated encouraging Phase 2 data showing significant improvement in nerve fiber density and pain scores. With a strong intellectual property estate and a clear regulatory pathway, WinSanTor is positioned to address a large, underserved market. However, as a private company, its progress depends on successful trial execution, financing, and partnership development. The management team has deep expertise in neurology and drug development, with a track record of advancing candidates to late-stage trials.

Upcoming Catalysts (preview)

• Q4 2026Top-line Phase 3 data for WST-001 in diabetic peripheral neuropathy55% success
• Q2 2027Initiation of Phase 2/3 trial for chemotherapy-induced peripheral neuropathy70% success
• H1 2027Potential strategic partnership or financing for late-stage development60% success